Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies

Rondy, Marc; Kissling, Esther; Emborg, Hanne‐Dorthe; Gherasim, Alin; Pebody, Richard; Trebbien, Ramona; Pozo, Francisco; Larrauri, Amparo; McMenamin, Jim; Valenciano, Marta; I-Move,

doi:10.2807/1560-7917.es.2018.23.9.18-00086

Cited by 65 publications

(49 citation statements)

References 19 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We estimated an adjusted VE of 48.5% for all vaccines. The estimated VE in our sample is higher compared to figures reported in EU in the same season, for a similar population, all vaccines (35%) [23]. As 94% of the vaccinees in our population had received the TIVadj vaccine, we had the possibility to calculate brandspecific VE, which resulted comparable to figures reported for all vaccines, also when considering strain-specific VE.…”

Section: Discussionsupporting

confidence: 62%

Effectiveness of the trivalent MF59 adjuvated influenza vaccine in preventing hospitalization due to influenza B and A(H1N1)pdm09 viruses in the elderly in Italy, 2017 – 2018 season

Bella¹,

Gesualdo

Orsi

et al. 2019

Expert Review of Vaccines

View full text Add to dashboard Cite

Q4 � Background: Evidence on influenza vaccine effectiveness (VE) in preventing mortality and morbidity in the elderly is weak. Our aim was to measure the VE against severe outcomes in the elderly. Methods: We conducted a multicentre hospital-based test-negative design (TND) case-control study, during the 2017/18 season, in four Italian hospitals. The study population included individuals aged ≥65 years hospitalized with Severe Acute Respiratory Infections (SARI). Patients were classified as cases and controls based on the results of the PCR influenza testing. We estimated VE by virus subtypes and specific VE for the trivalent adjuvanted vaccine (TIVadj). Results: 502 patients with SARI were enrolled: 118 (23.5%) tested positive (cases) and 384 (76.5%) tested negative (controls) for influenza. The adjusted VE of 48.5% for all vaccines was comparable to the adjusted VE for the TIVadj vaccine (48.3%). Adjusted VE for the TIVadj vaccine was 67.5% for A(H1N1) pdm09 and 44.5% for B viruses. Conclusion: We show a moderate adjusted VE of the TIVadj against all viruses, a good adjusted VE against A(H1N1)pdm09 strains and a moderate adjusted VE against B strains, despite a mismatch between the B circulating lineage and the lineage included in the vaccine. This is likely due to the crossprotection among B strains induced by the TIVadj in elderly patients.

show abstract

Section: Discussionsupporting

confidence: 62%

Effectiveness of the trivalent MF59 adjuvated influenza vaccine in preventing hospitalization due to influenza B and A(H1N1)pdm09 viruses in the elderly in Italy, 2017 – 2018 season

Bella¹,

Gesualdo

Orsi

et al. 2019

Expert Review of Vaccines

View full text Add to dashboard Cite

show abstract

“…The IVE against influenza A(H3N2) from these studies across nine countries (including two multi-country I-MOVE/I-MOVE+ studies) ranged from −42% to 7%, with IVE of 36%-54% for influenza B and 55%-68% for influenza A(H1N1)pdm09. 4 The I-MOVE (Influenza-Monitoring of Vaccines in Europe) hospital network has provided annual IVE for participating hospitals across Europe since 2015. In 2017-18, we measured seasonal IVE against hospitalisation with influenza A(H3N2) and B among older adults (aged 65 years and over) in the European Union (EU) by age group, underlying co-morbid conditions, and vaccination in previous seasons.…”

Section: Introductionmentioning

confidence: 99%

Vaccine effectiveness against influenza A(H3N2) and B among laboratory‐confirmed, hospitalised older adults, Europe, 2017‐18: A season of B lineage mismatched to the trivalent vaccine

Rose¹,

Kissling²,

Gherasim

et al. 2020

Influenza Resp Viruses

Self Cite

View full text Add to dashboard Cite

Background: Influenza A(H3N2), A(H1N1)pdm09 and B viruses co-circulated in Europe in 2017-18, predominated by influenza B. WHO-recommended, trivalent vaccine components were lineage-mismatched for B. The I-MOVE hospital network measured 2017-18 seasonal influenza vaccine effectiveness (IVE) against influenza A(H3N2) and B among hospitalised patients (≥65 years) in Europe.Methods: Following the same generic protocol for test-negative design, hospital teams in nine countries swabbed patients ≥65 years with recent onset (≤7 days) severe acute respiratory infection (SARI), collecting information on demographics, vaccination status and underlying conditions. Cases were RT-PCR positive for influenza A(H3N2) or B; controls: negative for any influenza. "Vaccinated" patients had SARI onset >14 days after vaccination. We measured pooled IVE against influenza, adjusted for study site, age, sex, onset date and chronic conditions. Results:We included 3483 patients: 376 influenza A(H3N2) and 928 B cases, and 2028 controls. Most (>99%) vaccinated patients received the B lineage-mismatched trivalent vaccine. IVE against influenza A(H3N2) was 24% (95% CI: 2 to 40); 35% (95% CI: 6 to 55) in 65-to 79-year-olds and 14% (95% CI: −22 to 39) in ≥80-year-olds.Against influenza B, IVE was 30% (95% CI: 16 to 41); 37% (95% CI: 19 to 51) in 65-to 79-year-olds and 19% (95% CI: −7 to 38) in ≥80-year-olds. | 303 ROSE Et al.Conclusions: IVE against influenza B was similar to A(H3N2) in hospitalised older adults, despite trivalent vaccine and circulating B lineage mismatch, suggesting some cross-protection. IVE was lower in those ≥80 than 65-79 years. We reinforce the importance of influenza vaccination in older adults as, even with a poorly matched vaccine, it still protects one in three to four of this population from severe influenza. K E Y W O R D SEurope, hospital, influenza, older adults, test-negative design, vaccine effectiveness

show abstract

“…In conclusion, based on the above findings, the adequate epidemiological surveillance of respiratory viruses infections is highly recommended and mandatory in hospital settings, to improve the diagnosis, therapy and prognosis of hospitalized patients. In addition, flu vaccination of all people at risk and care staff must be pursued with a greater determination, in light of recent epidemiological evidence [36][37][38][39]. We feel that we must prepare to face the consequences of new possible epidemics from other respiratory viruses and we must learn to know them better and to discriminate between the different virus types and their clinical consequences [40].…”

Section: Discussionmentioning

confidence: 99%

Viruses of Respiratory Tract: an Observational Retrospective Study on Hospitalized Patients in Rome, Italy

et al. 2020

View full text Add to dashboard Cite

Respiratory tract infections account for high morbidity and mortality around the world. Fragile patients are at high risk of developing complications such as pneumonia and may die from it. Limited information is available on the extent of the circulation of respiratory viruses in the hospital setting. Most knowledge relates to influenza viruses (FLU) but several other viruses produce flu-like illness. The study was conducted at the University Hospital Policlinico Tor Vergata, Rome, Italy. Clinical and laboratory data from hospitalized patients with respiratory tract infections during the period October 2016-March 2019 were analysed. The retrospective analysis included 17 viral agents detected by FilmArray test and clinical data from medical records and hospital discharge sheets. Models were adjusted for relevant confounders such as clinical severity and risk of death, socio-demographic characteristics and surgical procedures. From a total of 539 specimens analysed, 180 (33.39%) were positive for one or more respiratory viruses. Among them, 83 (46.1 %) were positive for influenza viruses (FLU), 36 (20%) rhino/enteroviruses (RHV/EV), 17 (9.44%) human coronaviruses (HCOV-229E, -HKU1, -NL63, and -OC43), 17 (9.44%) respiratory syncytial virus, 15 (8.33%) human metapneumovirus (HMPV), 8 (4.44%) parainfluenza viruses (PIV) and 4 (2.22%) adenoviruses (ADV). The distribution of viral agents varied across age groups and month of detection. The positive specimens were from 168 patients [102 M, 66 F; median age (range): 64 years (19−93)]. Overall, 40% of them had a high-grade clinical severity and a 27% risk of death; 27 patients died and 22 of them (81.5%) had received a clinical diagnosis of pneumonia. Respiratory viral infections may have a severe course and a poor prognosis in hospitalized patients, due to underlying comorbidities. Monitoring the circulation of respiratory viruses in hospital settings is important to improve diagnosis, prevention and treatment.

show abstract

Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies

Cited by 65 publications

References 19 publications

Effectiveness of the trivalent MF59 adjuvated influenza vaccine in preventing hospitalization due to influenza B and A(H1N1)pdm09 viruses in the elderly in Italy, 2017 – 2018 season

Effectiveness of the trivalent MF59 adjuvated influenza vaccine in preventing hospitalization due to influenza B and A(H1N1)pdm09 viruses in the elderly in Italy, 2017 – 2018 season

Vaccine effectiveness against influenza A(H3N2) and B among laboratory‐confirmed, hospitalised older adults, Europe, 2017‐18: A season of B lineage mismatched to the trivalent vaccine

Viruses of Respiratory Tract: an Observational Retrospective Study on Hospitalized Patients in Rome, Italy

Contact Info

Product

Resources

About